ADCETRIS

Indicaton

SeaGen's lead product ADCETRIS® (brentuximab vedotin) is marketed in over 70 countries worldwide for the treatment of CD30-expressing lymphomas, in collaboration with Takeda Pharmaceutical Company Limited.

Therapeutic indications

Oncology

Type of product

Antibody

Table

Phase

Marketed
Partnering status

Partnered
Partner

Takeda Pharmaceutical Company Limited.
Available in

EU, US, LATAM, JAPAC, Switzerland

You may also be interested in

Herzuma (trastuzumab)

Multiple indications in metastatic breast cancer, early breast cancer and metastatic gastric cancer

Marketed

Truxima (rituximab)

Multiple indications in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis, Granulomatosis with polyangiitis and microscopic polyangiitis and Pemphigus vulgaris

Marketed

3D CoSeedis in chip Assays

Preclinical 3D Study models for oncology and neurology.

Marketed